These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20518590)

  • 1. Medicare Part D Coverage Gap Discount Program beginning in 2011.
    Cahill JA
    J Manag Care Pharm; 2010 Jun; 16(5):367-8. PubMed ID: 20518590
    [No Abstract]   [Full Text] [Related]  

  • 2. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes.
    Fung V; Mangione CM; Huang J; Turk N; Quiter ES; Schmittdiel JA; Hsu J
    Health Serv Res; 2010 Apr; 45(2):355-75. PubMed ID: 20050931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A submission from the National Association of Health Underwriters.
    Garner JD
    J Women Aging; 2010; 22(2):81-2. PubMed ID: 20408029
    [No Abstract]   [Full Text] [Related]  

  • 4. How do seniors respond to 100% cost-sharing for prescription drugs? Quality of the evidence underlying opinions about the Medicare Part D coverage gap.
    Fairman KA; Curtiss FR
    J Manag Care Pharm; 2011 Jun; 17(5):382-92. PubMed ID: 21657807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare: Ninth Circuit limits rates providers can charge Medigap insurers.
    Caldie E
    J Law Med Ethics; 2003; 31(1):159-60. PubMed ID: 12762112
    [No Abstract]   [Full Text] [Related]  

  • 6. Changes loom as most-popular Medigap plans face extinction.
    Herman B
    Mod Healthc; 2016 Jul; 46(26-27):10-11. PubMed ID: 30480892
    [No Abstract]   [Full Text] [Related]  

  • 7. Medigap coverage and Medicare spending: a second look.
    Lemieux J; Chovan T; Heath K
    Health Aff (Millwood); 2008; 27(2):469-77. PubMed ID: 18332504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent proposals to limit Medigap coverage and modify Medicare cost sharing.
    Linehan K
    Issue Brief George Wash Univ Natl Health Policy Forum; 2012 Feb; (845):1-19. PubMed ID: 22420066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare supplemental insurance (Medigap).
    Stein N
    Issue Brief Cent Medicare Educ; 2003; 4(6):1-6. PubMed ID: 14503483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Private, individual drug coverage in the current Medicare market.
    Boccuti C; Moon M
    Policy Brief Commonw Fund; 2003 Oct; (679):1-10. PubMed ID: 14562796
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: Medicare Part D.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482890
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug coverage for Medicare beneficiaries: why protection may be in jeopardy.
    Briesacher B; Stuart B; Shea D
    Issue Brief (Commonw Fund); 2002 Jan; (505):1-8. PubMed ID: 11922051
    [No Abstract]   [Full Text] [Related]  

  • 13. In-gap discounts in Medicare Part D and specialty drug use.
    Jung J; Xu WY; Cheong C
    Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access to Medicare Part D gap coverage more scarce in 2007.
    Consult Pharm; 2007 Jan; 22(1):60-1. PubMed ID: 17380599
    [No Abstract]   [Full Text] [Related]  

  • 15. The state of the medigap market in Massachusetts.
    Miller M; Turnbull N
    Issue Brief (Mass Health Policy Forum); 1998 Apr; (1):1-21. PubMed ID: 12769084
    [No Abstract]   [Full Text] [Related]  

  • 16. Digesting the doughnut hole.
    Joyce GF; Zissimopoulos J; Goldman DP
    J Health Econ; 2013 Dec; 32(6):1345-55. PubMed ID: 24308883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.
    Hsu J; Fung V; Price M; Huang J; Brand R; Hui R; Fireman B; Newhouse JP
    JAMA; 2008 Apr; 299(16):1929-36. PubMed ID: 18430912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 20. Socioeconomic differences in Medicare supplemental coverage.
    Pourat N; Rice T; Kominski G; Snyder RE
    Health Aff (Millwood); 2000; 19(5):186-96. PubMed ID: 10992668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.